Akebia Therapeutics (AKBA) Total Current Liabilities (2016 - 2025)
Akebia Therapeutics (AKBA) has disclosed Total Current Liabilities for 10 consecutive years, with $162.9 million as the latest value for Q4 2025.
- Quarterly Total Current Liabilities rose 101.37% to $162.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $162.9 million through Dec 2025, up 101.37% year-over-year, with the annual reading at $162.9 million for FY2025, 101.37% up from the prior year.
- Total Current Liabilities for Q4 2025 was $162.9 million at Akebia Therapeutics, up from $133.4 million in the prior quarter.
- The five-year high for Total Current Liabilities was $261.1 million in Q4 2021, with the low at $65.7 million in Q3 2024.
- Average Total Current Liabilities over 5 years is $139.7 million, with a median of $124.1 million recorded in 2022.
- The sharpest move saw Total Current Liabilities tumbled 66.09% in 2023, then skyrocketed 102.98% in 2025.
- Over 5 years, Total Current Liabilities stood at $261.1 million in 2021, then crashed by 50.38% to $129.5 million in 2022, then decreased by 22.9% to $99.9 million in 2023, then decreased by 18.98% to $80.9 million in 2024, then soared by 101.37% to $162.9 million in 2025.
- According to Business Quant data, Total Current Liabilities over the past three periods came in at $162.9 million, $133.4 million, and $118.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.